Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8445858 | 0.81 | TDP1 (0.48) | — | |
| SCHEMBL4351612 | 0.77 | TDP1 (0.66) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL3040144 | 0.77 | ALDH1A1 (0.53) | KMT2A | |
| SCHEMBL661168 | 0.73 | QPCT (0.52) | — | |
| SCHEMBL8445961 | 0.73 | CREBBP (0.50) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL661173 | 0.73 | QPCT (0.51) | — | |
| SCHEMBL6790333 | 0.73 | TDP1 (0.71) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL2604742 | 0.71 | TDP1 (0.75) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL8862728 | 0.71 | TDP1 (0.75) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL8862878 | 0.71 | TDP1 (0.75) | CHRM2MEN1CYP1A2CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159431-A1 | Substituted alkyl uracils and thereof | BAYER HEALTHCARE AG (DE) | 2005-07-21 | — | — | US | disclosed |
| EP-1467975-A1 | SUBSTITUTED ALKYL URACILS AND THE USE THEREOF | Bayer HealthCare AG (DE) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003059892-A1 | SUBSTITUTED ALKYL URACILS AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2003-07-24 | — | — | WO | disclosed |
| EP-0618907-B1 | 1-(ARYLALKYL-AMINOALKYL)IMIDAZOLE DERIVATIVES, PROCESSES OF PREPARATION AND USE AS THERAPEUTICAL AGENTS | BRITISH TECH GROUP INT (GB) | 1999-04-28 | — | — | EP | disclosed |
| US-5547972-A | 1-(ARLALKYLAMINOALKYL) IMIDAZOLE DERIVATIVES | THE BOOTS COMPANY PLC (GB) | 1996-08-20 | — | — | US | disclosed |
| EP-0618907-A1 | 1-(ARYLALKYL-AMINOALKYL)IMIDAZOLE DERIVATIVES, PROCESSES OF PREPARATION AND USE AS THERAPEUTICAL AGENTS | Knoll AG (DE) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993013075-A1 | 1-(ARYLALKYL-AMINOALKYL)IMIDAZOLE DERIVATIVES, PROCESSES OF PREPARATION AND USE AS THERAPEUTICAL AGENTS | THE BOOTS COMPANY PLC (GB) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159431-A1 | Substituted alkyl uracils and thereof | UNG, UMPS, TYMP | RXFP1 4827/4885CHRM2 4460/4885MEN1 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.